IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, an ...
5d
Is Erasca (ERAS) Quietly Reframing Its RAS Strategy With Tango’s Dual-Target Trial Collaboration?
In early March 2026, Tango Therapeutics and Erasca announced a clinical trial collaboration and supply agreement to test Erasca’s pan-RAS molecular glue ERAS-0015 with Tango’s PRMT5 inhibitor ...
"This study establishes MTAP-del as a biomarker in bladder cancer. We are now ready for a trial in MTAP-del bladder cancer in combination with other inhibitors of the pathway." --Joaquim Bellmunt, MD, ...
MTAP encodes methylthioadenosine phosphorylase, an enzyme in the methionine salvage pathway that recycles methylthioadenosine to methionine. The gene resides on chromosome 9p21.3, adjacent to the ...
Multimodal integration of VI-RADS, radiomics, and deep learning features for prediction of pathology and prognosis in bladder cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary ...
US-based digital networking solutions provider mTap has announced its launch in India, offering a platform for individuals and businesses to make lasting connections. mTap's digital business card ...
IDEAYA Biosciences begins patient dosing in phase 1 trial of IDE892, a potential best-in-class PRMT5 inhibitor for MTAP-deleted solid tumours: South San Francisco, California Tues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results